A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

NCT03948763 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

70

Enrollment

INDUSTRY

Sponsor class

Stopped Business Reasons

Conditions

Neoplasms
Carcinoma, Non-Small-Cell Lung
Pancreatic Neoplasms
Colorectal Neoplasms

Interventions

BIOLOGICAL: V941
BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]